The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis

Zanten, Daniel Veldhuijzen van; Buganza, Elizabeth; Abraldes, Juan G.

doi:10.1016/j.cld.2021.01.002

Cited by 23 publications

(9 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher HVPG R20 mm Hg (high-risk PHT, high-risk portal hypertension [HRPH]), is associated with bleeding control failure, rebleeding, and mortality. [2][3][4][5] Therefore, continuous HVPG monitoring plays a significant role in the primary prophylaxis and therapeutic management of patients with PHT. However, transjugular HVPG measurement is invasive, expensive, and has professional barriers, which limits its clinical use in PHT management.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension

Huang

et al. 2022

Cell Reports Medicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…A higher HVPG ≥20 mm Hg (high-risk PHT, high-risk portal hypertension [HRPH]), is associated with bleeding control failure, rebleeding, and mortality. 2 , 3 , 4 , 5 …”

Section: Introductionmentioning

confidence: 99%

An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension

Huang

et al. 2022

Cell Reports Medicine

View full text Add to dashboard Cite

“…Patients with cirrhosis with a HVPG >10 mmHg have clinically significant PH and are at risk of complications. 3,41 The von Willebrand factor was reported as a novel noninvasive predictor of PH. [42][43][44] The von Willebrand antigen-toplatelet ratio is a convenient measure to diagnose clinically significant PH independently of CPS.…”

Section: Prognostic Biomarkers Of Lc Complicationmentioning

confidence: 99%

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience

et al. 2021

View full text Add to dashboard Cite

Liver cirrhosis is the final stage of chronic liver disease (CLD) and is associated with high morbidity and mortality. Various complications such as portal hypertension, ascites retention, hepatic encephalopathy, and hepatorenal syndrome deeply affect patient outcome. The most common tools to predict the outcome of a CLD patient include the following: assessing severity of portal hypertension; scoring systems such as the model of end‐stage liver disease and Child–Pugh score and blood biomarkers related to complications and/or survival rate. In this article, we summarize recent studies of noninvasive markers for predicting impending complications related to CLD and discuss the clinical value of currently available blood biomarkers based on evidence from the literature. In addition, noninvasive blood biomarker assays for different prognostic functions were validated on 113 liver cirrhosis patients at our institution using Kaplan–Meier curve analysis to confirm that these markers can satisfactorily predict CLD‐related patient death.

show abstract

“…Portal hypertension is defined as a portal pressure gradient (PPG) >6 mmHg or hepatic venous pressure gradient (HVPG) >5 mmHg. 1,2 The condition is often accompanied by gastroesophageal varices, ascites, and splenomegaly. The pathogenesis of portal hypertension involves multifaceted cellular and molecular mechanisms, including dysfunction of liver sinusoidal endothelial cells (LSEC), activation of hepatic stellate cells (HSC), dysregulation of endogenous hydrogen sulfide (H 2 S) synthesis, and hypoxia-induced angiogenic responses.…”

Section: Introductionmentioning

confidence: 99%

Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension

Yang¹,

Tan²,

Gao³

et al. 2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

The pathogenesis of portal hypertension remains unclear, and is believed to involve dysfunction of liver sinusoidal endothelial cells (LSEC), activation of hepatic stellate cells (HSC), dysregulation of endogenous hydrogen sulfide (H 2 S) synthesis, and hypoxia-induced angiogenic responses. H 2 S, a novel gas transmitter, plays an important role in various pathophysiological processes, especially in hepatic angiogenesis. Inhibition of endogenous H 2 S synthase by pharmaceutical agents or gene silencing may enhance the angiogenic response of endothelial cells. Hypoxia-inducible factor-1 (HIF-1) is the main transcription factor of hypoxia, which induces hepatic angiogenesis through up-regulation of vascular endothelial growth factor (VEGF) in HSC and LSEC. H 2 S has also been shown to be involved in the regulation of VEGF-mediated angiogenesis. Therefore, H 2 S and HIF-1 may be potential therapeutic targets for portal hypertension. The effects of H 2 S donors or prodrugs on the hemodynamics of portal hypertension and the mechanism of H 2 S-induced angiogenesis are promising areas for future research.

show abstract

The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis

Cited by 23 publications

References 79 publications

An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension

An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience

Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension

Contact Info

Product

Resources

About